Blueprint Medicines Corporation (BPMC): Price and Financial Metrics
Today's Latest Price: $96.91 USD
Jan 26 6:55pm Add BPMC to Watchlist Sign Up
Buy & Hold Grade
Peer Grade Industry Rank
BPMC Stock Summary Of note is the ratio of Blueprint Medicines Corp's sales and general administrative expense to its total operating expenses; only 16.52% of US stocks have a lower such ratio. In terms of twelve month growth in earnings before interest and taxes, Blueprint Medicines Corp is reporting a growth rate of -187.63%; that's higher than merely 10.34% of US stocks. As for revenue growth, note that BPMC's revenue has grown 4,965.96% over the past 12 months; that beats the revenue growth of 99.77% of US companies in our set. Stocks with similar financial metrics, market capitalization, and price volatility to Blueprint Medicines Corp are CLSD, TBIO, LIFE, DRNA, and RCUS. BPMC's SEC filings can be seen here. And to visit Blueprint Medicines Corp's official web site, go to www.blueprintmedicines.com.
BPMC Price/Volume Stats
Blueprint Medicines Corporation (BPMC) Company Bio
Blueprint Medicines Corporation makes kinase drugs to treat patients with genomically defined diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts.
BPMC Latest News Stream
All News Types
Loading, please wait...
Latest BPMC News From Around the Web
Below are the latest news stories about Blueprint Medicines Corp that investors may wish to consider to help them evaluate BPMC as an investment opportunity.
AzurRX (AZRX) is developing its pipeline candidate, MS1819, as monotherapy as well in combination with standard of care for treating exocrine pancreatic insufficiency in patients with cystic fibrosis.
Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company's research and development organization. Effective as of January 11, 2021, Becker Hewes, M.D., currently Senior Vice President, Clinical…
Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day
Read More 'BPMC' Stories Here
BPMC Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.8158 seconds.